Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Glioma Stories

2012-03-21 10:25:03

ALLEGAN, Mich., March 21, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received a final "Approval for Registration" letter from the Australian Therapeutic Goods Administration permitting the Company to sell generic temozolomide in Australia. The letter also states that bioequivalence was met between the brand product, Temodar®, and the Company's generic temozolomide, enabling listing on the Pharmaceutical Benefits Scheme or PBS. (Logo:...

2012-03-16 11:13:08

Brain-tumor cells that are infected with a cancer-killing virus release a protein "alarm bell" that warns other tumor cells of the impending infection and enables them to mount a defense against the virus, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James). The infected tumor cells release a protein called CCN1 into the narrow space between...

Researchers Create Living Model Of Brain Tumor
2012-02-17 04:58:29

Brown University scientists have created the first three-dimensional living tissue model, complete with surrounding blood vessels, to analyze the effectiveness of therapeutics to combat brain tumors. The 3-D model gives medical researchers more and better information than Petri dish tissue cultures. The researchers created a glioma, or brain tumor, and the network of blood vessels that surrounds it. In a series of experiments, the team showed that iron-oxide nanoparticles ferrying the...

2012-02-09 09:00:00

RIDGEWOOD, N.J., Feb. 9, 2012 /PRNewswire-USNewswire/ -- The Valley Hospital is now offering patients with newly diagnosed glioblastoma multiforme (GBM) (brain tumor) the opportunity to take part in a clinical trial that produces and uses a vaccine produced from patients' own tissue. The study is being conducted to learn if it can improve the outcome for patients in the fight against this aggressive and deadly form of brain cancer. The Phase Two trial, headed by principal...

2012-02-07 19:19:17

Researchers at Virginia Commonwealth University Medical Center's VCU Massey Cancer Center and Harold F. Young Neurosurgical Center (Richmond, VA) and Old Dominion University (Norfolk, VA) have discovered that suppression of Wilms tumor 1 protein (WT1) results in downregulation of CD97 gene expression in three glioblastoma cell lines and reduces the characteristic invasiveness exhibited by glial tumor cells. This finding is announced in the article, "Novel report of expression and function of...

2012-02-07 09:30:00

VANCOUVER, British Columbia , Feb. 7, 2012 /PRNewswire/ -- Del Mar Pharmaceuticals today announced that a pre-clinical abstract entitled, "VAL083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme," will be presented April 1, 2012 at the American Association for Cancer Research (AACR) Annual Meeting, which is being held March 31 thru April 4, 2012 in Chicago, USA....

2012-02-03 19:00:09

Study conducted in mice treated with Toca 511 and 5-FC Tocagen Inc. today announced the publication of data showing the company's investigational treatment for high grade glioma eradicates brain tumors and provides a dramatic survival benefit in mouse models of glioblastoma. Almost all mice receiving the top dose of Toca 511 followed by 5-FC were still alive at 180 days, which was the termination date for the experiment, whereas all control mice died by day 43. The article was published...

2012-02-06 07:00:00

WASHINGTON and NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer. The collaboration will explore the capabilities of Exosome RNA biofluid-based diagnostic technology for early identification, progression monitoring and disease risk stratification...

2012-02-03 07:00:00

SAN DIEGO, Feb. 3, 2012 /PRNewswire/ -- Tocagen Inc. today announced the publication of data showing the company's investigational treatment for high grade glioma eradicates brain tumors and provides a dramatic survival benefit in mouse models of glioblastoma. Almost all mice receiving the top dose of Toca 511 followed by 5-FC were still alive at 180 days, which was the termination date for the experiment, whereas all control mice died by day 43. The article was published today in...

2012-01-31 10:39:00

DETROIT, Jan. 31, 2012 /PRNewswire/ -- Henry Ford Hospital's Hermelin Brain Tumor Center is the first U.S. hospital to start a new clinical trial for Toca 511 & Toca FC, a combination therapy under investigation for high-grade glioma (HGG), a fast growing, brain cancer that often recurs even after surgery, radiation treatment and chemotherapy. The investigational treatment combines Toca 511 (vocimagene amiretrorepvec), a biologic drug, with Toca FC, an extended-release tablet...